Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Yearshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use the Pfizer-BioNTech COVID-19 Vaccine for

Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Triple-Negative Breast Cancer (TNBC)Pexels:
Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Triple-Negative Breast Cancer (TNBC)


Agilent Technologies Inc. (NYSE: A) today announced that its PD-L1 IHC 22C3 pharmDx assay is now labelled for use in TNBC in the European Union.



PD-L1 expression is a critical biomarker for

Agilent to Webcast Fourth-Quarter Fiscal Year 2021 Financial Results Presentation:
Agilent to Webcast Fourth-Quarter Fiscal Year 2021 Financial Results Presentation


Agilent Technologies Inc. (NYSE: A) will release fourth-quarter fiscal year 2021 financial results after the stock market closes on Monday, November 22. The company will host a live webcast of its

Pfizer and BioNTech to Provide U.S. Government an Additional 50 Million Pediatric Doses of COVID-19 Vaccine to Support Further Preparedness for Future Needshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech to Provide U.S. Government an Additional 50 Million Pediatric Doses of COVID-19 Vaccine to Support Further Preparedness for Future Needs


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government has purchased 50 million more doses of the companies’ COVID-19 vaccine. The U.S. will receive these

Humana Healthy Horizons Launches Louisiana Statewide Mobile Clinic Initiative with Ochsner Health: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Healthy Horizons Launches Louisiana Statewide Mobile Clinic Initiative with Ochsner Health


From New Orleans to Baton Rouge to Lafayette, Shreveport and surrounding rural areas, two new mobile clinics will soon bring a wide variety of health services to thousands of Louisianans. It’s all

Agilent Commits to Net-Zero Greenhouse Gas Emissions by 2050:
Agilent Commits to Net-Zero Greenhouse Gas Emissions by 2050


Agilent Technologies, Inc. (NYSE: A) today announced its commitment to achieve net-zero greenhouse gas emissions no later than 2050. The commitment adds to the global effort by governments

Humana Expands Medicare Advantage Network to Include Northeast Georgia Health System, Longstreet Clinic and Others Across Region: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Expands Medicare Advantage Network to Include Northeast Georgia Health System, Longstreet Clinic and Others Across Region


Northeast Georgia Health System (NGHS), a non-profit that cares for more than 1 million people across more than 18 counties, and leading health and well-being company Humana Inc. (NYSE: HUM) have

Waters and Sartorius Partner to Help Bioprocess Scientists Accelerate Clone Selection and Process Development: https://mms.businesswire.com/media/20191105005256/en/560437/5/Waters_logo_K.jpg
Waters and Sartorius Partner to Help Bioprocess Scientists Accelerate Clone Selection and Process Development


Waters Corporation (NYSE: WAT) and Sartorius (DAX: SRT:GR) announced today they will partner to provide bioprocess experts with direct access to high-quality mass spectrometry (MS) data to

FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech COVID-19 Vaccine in Children 5 to <12 Yearshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech COVID-19 Vaccine in Children 5 to <12 Years


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted

New Poll Reveals Significant Changes to Seniors’ Lives and Values Since Onset of COVID-19 Pandemic
New Poll Reveals Significant Changes to Seniors’ Lives and Values Since Onset of COVID-19 Pandemic


Findings released today from a new Humana Inc. (NYSE: HUM) national poll indicate the extent to which seniors’ health – and their values related to health – have been affected since the onset of

Humana Expands Footprint in Maryland: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Expands Footprint in Maryland


Leading health and well-being company Humana Inc. (NYSE: HUM) is expanding its footprint in Maryland and, for the first time, offering affordable Humana Medicare Advantage plans to beneficiaries

Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma:
Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma


Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with

IQVIA Reports Third-Quarter 2021 Results and Raises Full-Year 2021 Guidance
IQVIA Reports Third-Quarter 2021 Results and Raises Full-Year 2021 Guidance


IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported

Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccinehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced topline results from a Phase 3 randomized, controlled trial evaluating the efficacy and safety of a 30-µg booster dose of the

Advisory Committee on Immunization Practices Votes to Recommend Routine Use of Pfizer’s PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) in Adultshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Advisory Committee on Immunization Practices Votes to Recommend Routine Use of Pfizer’s PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) in Adults


Pfizer Inc. (NYSE:PFE) announced today that the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend PREVNAR 20 (Pneumococcal

Waters and University of Delaware Announce Bioprocessing Innovation Partnership, Plan 2022 Opening of Immerse Delaware Lab: https://mms.businesswire.com/media/20191105005256/en/560437/5/Waters_logo_K.jpg
Waters and University of Delaware Announce Bioprocessing Innovation Partnership, Plan 2022 Opening of Immerse Delaware Lab


Waters Corporation (NYSE:WAT) and the University of Delaware today announced a five-year research partnership to develop new analytical solutions for bioprocessing and biomanufacturing. Key to this

Humana Expands Footprint, Health Plan Choices in New Jersey: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Expands Footprint, Health Plan Choices in New Jersey


Leading health and well-being company Humana Inc. (NYSE: HUM) is expanding health plan choices for Medicare beneficiaries in New Jersey by once again adding counties in which its 2022 Humana

Humana Healthy Horizons in Kentucky Announces $207,000 Investment to Reduce “Digital Divide” and Improve Access to Health Care in Lyon County, KY: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Healthy Horizons in Kentucky Announces $207,000 Investment to Reduce “Digital Divide” and Improve Access to Health Care in Lyon County, KY


Humana Healthy Horizons in Kentucky, Humana’s (NYSE: HUM) Kentucky Medicaid Plan, is pleased to announce a $207,000 investment that will upgrade infrastructure in Lyon County, KY in order to

For First Time, Humana Offering Medicare Advantage Plans in Connecticut: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
For First Time, Humana Offering Medicare Advantage Plans in Connecticut


Leading health and well-being company Humana Inc. (NYSE: HUM) is expanding health plan choices for Medicare beneficiaries in Connecticut by offering affordable Humana Medicare Advantage plans in

Pfizer’s Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermatitishttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer’s Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermatitis


Pfizer Inc. (NYSE: PFE) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the 100 mg and

Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer:
Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer


Agilent Technologies Inc. (NYSE: A) today announced its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now FDA approved as an aid in identifying patients with early breast cancer (EBC) at high risk of

Humana Continues Extensive Statewide Expansion in Tennessee: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Continues Extensive Statewide Expansion in Tennessee


Leading health and well-being company Humana Inc. (NYSE: HUM) today announced another major expansion of its Medicare Advantage (MA) offerings across Tennessee for the 2022 plan year. It’s part of

Humana Expands Access to Affordable Medicare Options in Eastern North Carolina: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Expands Access to Affordable Medicare Options in Eastern North Carolina


Leading health and well-being company Humana Inc. (NYSE: HUM) announced today it is introducing a new affordable, whole person health care Medicare Advantage PPO plan in rural communities located

PerkinElmer Receives FDA Emergency Use Authorization for Respiratory SARS-CoV-2 Panel : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24701/263px-PerkinElmer.svg.png
PerkinElmer Receives FDA Emergency Use Authorization for Respiratory SARS-CoV-2 Panel


PerkinElmer, Inc. (NYSE: PKI) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel 1

Humana Foundation Donates $200,000 to Recovery Efforts for Louisianans Impacted by Hurricane Ida: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Foundation Donates $200,000 to Recovery Efforts for Louisianans Impacted by Hurricane Ida


The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 40 years, is donating $200,000 to the recovery and relocation efforts for those impacted by Hurricane Ida in